Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2021-02-26 Earnings Release
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Half yearly financial reports and audit reports/limited reviews / Half yearly financial report
Earnings Release Classification · 98% confidence The document is explicitly titled "*PRESS RELEASE*" and announces "NANOBIOTIX 2020 Q4 AND ANNUAL REVENUES". It presents key financial highlights for the fourth quarter and the full year ended December 31, 2020, including revenue tables and cash position updates. This format, focusing on key figures immediately following the end of a reporting period, aligns perfectly with an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim Report (IR), nor is it a transcript (CT) or a presentation (IP). The document also mentions the upcoming Annual General Meeting (AGM) date, confirming the context of year-end reporting. Q4 2020
2021-02-26 English
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
Earnings Release Classification · 98% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and its main subject is the announcement of Nanobiotix's revenue for the fourth quarter and the full year 2020 ("NANOBIOTIX ANNONCE SON CHIFFRE D'AFFAIRES DU QUATRIÈME TRIMESTRE ET DE L'EXERCICE 2020"). It presents key financial figures (Chiffre d'affaires 2020, T4 2020) and operational highlights for the period. This structure—a press release summarizing period-end financial results—is characteristic of an Earnings Release (ER). Although it contains some forward-looking statements and mentions future events (like the AGM date), its primary function is the initial disclosure of period results, which aligns best with the ER definition, rather than the comprehensive Annual Report (10-K) or the Interim Report (IR), as it focuses on highlights and key metrics rather than a full statutory filing. Q4 2020
2021-02-26 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and Règlement Général de l'Autorité des Marchés Financiers - AMF) and provides a monthly update (as of January 31, 2021) on the total number of shares and voting rights. This type of regular disclosure regarding share capital structure and voting rights is a specific regulatory requirement, often related to major shareholdings or capital changes, but the core content is a direct notification of the current share count. This aligns best with 'Major Shareholding Notification' (MRQ) as it details the base for calculating ownership thresholds, or potentially 'Share Issue/Capital Change' (SHA). However, since it is a recurring, mandatory monthly disclosure of the total share count used for threshold calculations, it is most closely related to the reporting of significant ownership changes or capital structure status, which MRQ often encompasses in practice for these specific monthly updates in European contexts, or it could be considered a general regulatory filing (RNS). Given the specific focus on the total number of voting rights and shares, which is a prerequisite for Major Shareholding Notifications, MRQ is a strong candidate. If MRQ is strictly for crossing thresholds, then SHA (Share Issue/Capital Change) is relevant if the number changed, but this is a routine update. Since it is a mandatory, specific regulatory disclosure about the capital base, and not a general announcement of a report, I will classify it as MRQ, as these monthly updates are often filed in conjunction with or as part of major shareholding disclosure requirements.
2021-02-10 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a collaboration agreement between Curadigm (a subsidiary of Nanobiotix) and Sanofi regarding gene therapy technologies. This type of announcement, detailing a new business development, partnership, or strategic move, is typically classified as a general corporate announcement. Since it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR), and it is not a proxy statement (DEF 14A) or a management discussion (MDA), the most appropriate category is the general regulatory/corporate announcement fallback, RNS, as it is a public disclosure of material information. It is not a short announcement pointing to a separate report, so RPA is less suitable than RNS for this substantive press release content.
2021-01-25 French
Inside Information / Other news releases
Regulatory Filings Classification · 96% confidence The document is clearly labeled as a "PRESS RELEASE" and announces a new collaboration agreement between Nanobiotix subsidiary Curadigm and Sanofi regarding gene therapy development. This type of announcement, detailing a business development, partnership, or significant corporate event, is typically classified as a general regulatory announcement or a specific corporate action announcement. Since there is no specific category for 'Partnership Announcement' and it is not a formal financial report (like 10-K, IR, ER), nor is it a management change (MANG) or director dealing (DIRS), it falls best under the general regulatory/corporate announcement category. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a press release detailing a significant business development that isn't covered by other specific codes like CAP (financing) or TAR (M&A). The document length (8974 chars) is substantial, indicating it is the primary content, not just a brief announcement of a report (ruling 2 does not apply).
2021-01-25 English
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is explicitly titled "PRESS RELEASE" and announces "Positive first results for novel NBTXR3 in rectal cancer study at ASCO-GI 2021." It details key efficacy and safety data points from a clinical trial (Phase Ib/II) and mentions the data presentation at a medical symposium (ASCO-GI 2021). This format—a concise announcement of recent financial or operational milestones, often including preliminary data or event summaries—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational news. Since it is not a full, comprehensive report (like 10-K or IR), nor a transcript (CT), nor a specific regulatory filing like DIRS or DIV, the best fit among the provided options for a company announcing key operational/clinical results is the Earnings Release (ER) category, which often encompasses such operational updates, even if not strictly tied to quarterly financials. Given the context of clinical trial results being announced via press release, ER is the most appropriate classification for a major operational update.
2021-01-15 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.